PAVmed Inc PAVM 深 滬
已收盤 12-12 16:00:00 美东时间
0.33
-0.020
-5.71%
華盛通- 最 高0.363
- 今 開0.347
- 成交量 30.28万股
- 最 低 0.33
- 昨 收 0.35
- 總市值 926.82万
- 52周最高 0.8974
- 市盈率 靜 0.67
- 換手率 1.08%
- 52周最低 0.304
- 委 比 78.57%
- 總股本 2808.54万
- 歷史最高 228.0532
- 量 比 0.82
- 振 幅 9.43%
- 歷史最低 0.304
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $17
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $20 to $17.
12-10 18:27
PAVmed Approves Reverse Stock Split Amendment
PAVmed ( ($PAVM) ) has issued an update. On December 5, 2025, PAVmed Inc. held ...
12-06 05:53
PAVmed Q3 Adj. EPS $(0.02) Beats $(0.20) Estimate, Sales $5.000K Miss $12.500K Estimate
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.20) by 90 percent. This is a 96.3 percent increase over losses of $(0.54) per share from the same
11-13 21:48
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
美股机会日报 | 大摩警示！通胀骤降才是美股最大威胁；见证历史！黄金期货触及4000美元大关
大摩警示！通胀骤降才是美股最大威胁；见证历史！黄金期货触及4000美元大关；矿产勘探公司TMQ飙涨超200%，美国政府宣布将收购公司10%股份>>
10-07 19:34
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $20
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $19 to $20.
10-06 18:02
Lucid Diagnostics Reveals Proposed Public Offering of Common Stock; Size Not Disclosed
NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc.
09-10 04:02
PAVmed Announces It Has Signed A Non-Binding LOI With Duke University To License Advanced Esophageal Precancer Detection Technology Through A New Subsidiary
Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasiaLucid Diagnostics to collaborate with PAVmed as a strategic and equity
08-26 20:08
